相关实验视频

Updated: Jun 11, 2025

In vitro Assessment of Cardiac Reprogramming by Measuring Cardiac Specific Calcium Flux with a GCaMP3 Reporter

In vitro Assessment of Cardiac Reprogramming by Measuring Cardiac Specific Calcium Flux with a GCaMP3 Reporter

Published on: February 22, 2022

基因表达特征,潜在的目标和治疗心脏重塑的治疗方法

Dong Fan¹, Han Feng², Mengyu Song³

¹Department of Pathophysiology, Zhuhai Campus of Zunyi Medical University, Zhuhai, 519041, China. dongfan@zmuzh.edu.cn.

Molecular and cellular biochemistry

|October 5, 2024

概括

这篇评论探讨了心脏重塑中的基因表达变化,这是心力衰竭的关键过程. 了解这些分子机制有助于开发心脏病的新疗法.

科学领域:

心血管生物学心血管生物学
分子医学是分子医学.
基因组学就是基因组学.

背景情况:

高血压和缺血性心脏病是全球心力衰竭和死亡的主要原因.
心脏重塑,包括缩,纤维化和细胞死亡,是这些疾病的核心.
动物模型对于研究心肌重塑过程至关重要.

研究的目的:

审查最近在心脏改造基因表达分析方面的进展.
为了阐明分子机制,基因功能,和信号通路涉及到心肌重塑.
讨论针对心脏病中的基因表达的治疗策略.

主要方法:

RNA测序和差异表达基因 (DEG) 分析是关键工具.
研究由压力过载,缺血-再输血,心肌梗塞和糖尿病引起的心肌重塑.
在改造过程中对基因调节中的性别差异和炎症的分析.

主要成果:

基因表达造型揭示了对心脏重塑不同阶段的分子洞察力.
确定与心力衰竭相关的关键信号通路和基因功能.
了解性和炎症如何影响心脏重塑中的基因表达.

结论:

基因表达分析为心力衰竭中药物查提供了潜在的标.
调节基因表达为心肌重塑提供了新兴的治疗策略.
对DEG和调控机制的进一步研究可以促进心血管疾病的治疗.

关键词:

进行心脏重塑.不同表达的基因.心脏衰竭是因为心脏衰竭.压力过载的压力过载有关RNA测序的RNA测序

更多相关视频

Assessing Cardiac Reprogramming using High Content Imaging Analysis

Assessing Cardiac Reprogramming using High Content Imaging Analysis

Published on: October 26, 2020

Suppression of Pro-fibrotic Signaling Potentiates Factor-mediated Reprogramming of Mouse Embryonic Fibroblasts into Induced Cardiomyocytes

Suppression of Pro-fibrotic Signaling Potentiates Factor-mediated Reprogramming of Mouse Embryonic Fibroblasts into Induced Cardiomyocytes

Published on: June 3, 2018

相关概念视频

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...

Cardiomyopathy V: Interprofessional Care

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...